THE CELL HOLDS THE ANSWERS,

AND OUR TESTS UNLOCK THOSE ANSWERS TO EXTEND LIVES.

AR-V7 TEST

The AR-V7 test is the first and only Medicare reimbursed, clinically-validated, predictive circulating tumor cell (CTC) liquid biopsy test for metastatic castration-resistant prostate cancer (mCRPC). Requiring only a simple, non-invasive blood draw, this groundbreaking test empowers patients, with their doctors, the confidence to choose the most effective precision therapies.

DECISION POINT

For pharmaceutical and clinical investigation partners, our Decision Point program delivers a bias-free approach for cancer research, to develop clinical solutions that accelerate drug development and provide valuable insights into the dynamics of cancer growth, evolution and heterogeneity.

0
CANCER TYPES
0
ACADEMIC PARTNERS
0
PHARMACEUTICAL PARTNERS
0
PUBLICATIONS
>
0
CLINICAL TRIALS
>
0
SINGLE CTC GENOMES SEQUENCED
>
0
PATIENT SAMPLES CONTRACTED

WHAT SOURCES ARE SAYING

Latest Tweets